Generic Name and Formulations:
Dyphylline 200mg, 400mg; scored tabs.
Indications for LUFYLLIN:
For relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.
Individualize. Usual dose: up to 15mg/kg every 6 hours. Renal impairment: adjust dose.
Not for primary treatment of acute attack. Severe cardiac disease. Hypertension. Hyperthyroidism. Acute myocardial injury. Peptic ulcer. Pregnancy (Cat.C). Nursing mothers.
Toxicity with concomitant sympathomimetics. Potentiated by probenecid.
GI upset, epigastric pain, hematemesis, headache, irritability, restlessness, insomnia, hyperexcitability, agitation, muscle twitching, generalized clonic and tonic convulsions, palpitation, tachycardia, extrasystoles, flushing, hypotension, circulatory failure, ventricular arrhythmias, tachypnea, gross and microscopic hematuria, diuresis, hyperglycemia, inappropriate ADH syndrome.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib